The Diagnostic and Prognostic Value of Speckle Tracking Imaging in Septic Cardiomyopathy

The Diagnostic and Prognostic Value of Speckle Tracking Imaging in Septic Cardiomyopathy: a Prospective Cohort Study

The aim of this study is to explore if STI technology, especially TMAD, plays an important role in evaluating left ventricular longitudinal systolic function and discriminating SICM in patients with sepsis. The investigators also intend to prove that TMAD may have predictive value in patients with sepsis, which is worthy of in-depth study to find strong evidence-based medical evidence for subsequent clinical practical applications.

Study Overview

• Status: Recruiting
• Conditions: Sepsis; Cardiomyopathies; Echocardiography

Detailed Description

In order to explore if STI technology, especially TMAD, plays an important role in evaluating left ventricular longitudinal systolic function and discriminating SICM in patients with sepsis, the investigators intend to explore that TMAD may have predictive value in patients with sepsis, which is worthy of in-depth study to find strong evidence-based medical evidence for subsequent clinical practical applications.

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

• Study Contact: Name: Jieqiong Song; Phone Number: 13917056745; Email: song.jieqiong@zs-hospital.sh.cn

Study Locations

• China
  • Shanghai, China, 200032
    • Recruiting
    • 180 Fenglin Road
    • Contact: Jieqiong Song; Phone Number: 13917056745; Email: song.jieqiong@zs-hospital.sh.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

adult patients who are diagnosed as sepsis according to sepsis 3.0 criteria, excluding those with history of organic heart disease, heart failure, atrial fibrillation or holder of cardiac implanted device

Description

Inclusion Criteria:

• patients who are diagnosed as sepsis according to sepsis 3.0 criteria

Exclusion Criteria:

• patients with history of organic heart disease;
• patients with history of heart failure
• holder of cardiac implanted device;
• patients with history of atrial fibrillation;
• refusal to participate in the study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
28-day mortality	28-day mortality of sepsis	28 days

Collaborators and Investigators

• Sponsor: Shanghai Zhongshan Hospital
• Investigators: Principal Investigator: Jieqiong Song, Fudan University

Study record dates

Study Major Dates

• Study Start (Actual): December 18, 2022
• Primary Completion (Estimated): December 1, 2023
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: November 14, 2022
• First Submitted That Met QC Criteria: November 14, 2022
• First Posted (Actual): November 22, 2022

Study Record Updates

• Last Update Posted (Estimated): November 20, 2023
• Last Update Submitted That Met QC Criteria: November 15, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Cardiomyopathies
• Other Study ID Numbers: STI-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No